New fibroid drug ryeqo under scrutiny for blood clot risk
NCT ID NCT07173127
First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 26 times
Summary
This study looks at whether Ryeqo, a new hormone treatment for uterine fibroids, increases the risk of dangerous blood clots. Researchers will measure blood clotting markers in 30 women before and after 3 months of taking the drug. The goal is to better understand the safety of this treatment and help doctors choose the best option for each patient.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UTERINE FIBROID are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hôpitaux Universitaires de Genève
RECRUITINGGeneva, Canton of Geneva, 1205, Switzerland
Contact
Contact
Contact
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.